PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Fenbendazole and Cervical Cancer: What the Research Really Shows- In recent years, fenbendazole (often shortened to “fenben”)—a veterinary anti-parasite medication—has gained attention online as a possible cancer treatment. Patient stories and social media discussions have helped fuel interest, especially among people searching for inexpensive, repurposed therapies.
But what does scientific research actually show?
This post reviews the current evidence—from laboratory studies to early clinical observations—to help patients understand where fenbendazole stands today in cancer research.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths and taken great risks in an effort to manage my blood cancer. I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.
The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and cancer debate. Please scroll down the page, post a question or a comment if you have any questions.
If you’d like to learn more about repurposed drugs and cancer treatment, click now.
Thank you,
Cervical cancer begins in the cells of the cervix and is most commonly driven by persistent infection with high-risk strains of human papillomavirus (HPV).
Standard treatments include:
Despite these therapies, recurrence and treatment resistance remain major challenges, particularly in advanced cases.
Fenbendazole is part of a class of drugs called benzimidazoles, originally designed to kill parasites.
Interest in fenbendazole for cancer comes from:
However, interest ≠ evidence.
A 2025 preclinical study specifically examined fenbendazole in cervical cancer models:
👉 Read the study:
Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer
Key finding:
Fenbendazole suppressed tumor growth and improved survival in mouse models without obvious toxicity
Why this matters:
Fenbendazole appears to act through several anti-cancer mechanisms:
👉 Fenbendazole binds tubulin and disrupts microtubules
Closely related drugs (like mebendazole) show:
👉 Review:
Mebendazole as a Candidate for Drug Repurposing in Oncology
These findings support the biological plausibility of this drug class.
Despite promising lab results:
Example:
The bottom line:
👉 Preclinical success does NOT equal clinical effectiveness
The American Cancer Society overview on fenbendazole notes:
Fenbendazole:
👉 It has not been approved by the FDA for human use
Rather than relying on a single unproven drug, evidence supports a multi-modal strategy:
These approaches:
Fenbendazole is:
For cervical cancer patients:
👉 The smartest strategy is:
Fenbendazole sits in a category common in oncology:
“Biologically interesting, clinically unproven.”
For cervical cancer survivors and patients, the goal is not chasing hype—
it’s building a sustainable, evidence-based survivorship strategy.
Fenbendazole and Cervical Cancer Fenbendazole and Cervical Cancer Fenbendazole and Cervical Cancer